CRSP
CRISPR Therapeutics AG is a gene editing company. It is engaged in the development of CRISPR/Cas9-based therapeutics.
CRISPR Therapeutics AG (CRSP) is rated C+ (2.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B+); its weakest is Value (C-).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-11 | C- (1.9) | B+ (3.7) | C- (1.9) | C+ (2.7) | C+ (2.6) | C+ (2.6) |
| 2026-11-04 | D- (0.9) | B+ (3.8) | D+ (1.8) | B- (3.0) | C+ (2.7) | C (2.4) |
| 2026-10-28 | D- (0.9) | B+ (3.7) | D+ (1.8) | B- (2.9) | C+ (2.7) | C (2.4) |
| 2026-10-21 | D- (1.0) | B+ (3.7) | D+ (1.8) | B- (2.9) | C+ (2.6) | C (2.4) |
| 2026-10-14 | D- (1.0) | B+ (3.7) | D+ (1.8) | C+ (2.5) | C+ (2.6) | C (2.3) |